BACKGROUND: The aim of this study was to examine the relationship between trends in CD4 counts (slope) and HIV viral load (VL) after initiation of combination antiretroviral treatment (cART) in Asian patients in The TREAT Asia HIV Observational Database (TAHOD). METHODS: Treatment-naive HIV-infected patients who started cART with three or more and had three or more CD4 count and HIV VL tests were included. CD4 count slopes were expressed as changes of cells per microliter per year. Predictors of CD4 count slopes from 6 months after initiation were assessed by random-effects linear regression models. RESULTS: A total of 1676 patients (74% male) were included. The median time on cART was 4.2 years (IQR 2.5-5.8 years). In the final model...
INTRODUCTION The World Health Organization (WHO) recommends a CD4 cell count before starting anti...
BACKGROUND: Although the kinetics of CD4(+) cell counts have been extensively studied in antiretrovi...
ObjectiveTo assess whether the benefit of highly active antiretroviral therapies (HAART) is continui...
Background: The aim of this study was to examine the relationship between trends in CD4 counts (slop...
Abstract Background The aim of this study was to examine the relationship between trends in CD4 coun...
Introduction: Although antiretroviral therapy (ART) has been rapidly scaled up in Asia, most HIV-pos...
Background: Random effects models were used to explore how the shape of CD4 cell count responses aft...
Background Early initiation of combination antiretroviral therapy (cART), at higher CD4 cell coun...
Background Combination antiretroviral therapy (cART) has been shown to reduce mortality and morbidi...
The introduction of combination antiretroviral treatment (ART) has had substantial impact on the hum...
Early initiation of combination antiretroviral therapy (cART), at higher CD4 cell counts, prevents d...
Objective: To examine CD4 cell responses to combination antiretroviral therapy (cART) in patients en...
BACKGROUND: CD4+ cell counts reflect immunologic status of human immunodeficiency virus (HIV) patien...
BACKGROUND: CD4+ T-cell recovery in patients with continuous suppression of plasma HIV-1 viral load ...
Background: Currently, because of the wide availability and free service of HAART, HIV/AIDS related ...
INTRODUCTION The World Health Organization (WHO) recommends a CD4 cell count before starting anti...
BACKGROUND: Although the kinetics of CD4(+) cell counts have been extensively studied in antiretrovi...
ObjectiveTo assess whether the benefit of highly active antiretroviral therapies (HAART) is continui...
Background: The aim of this study was to examine the relationship between trends in CD4 counts (slop...
Abstract Background The aim of this study was to examine the relationship between trends in CD4 coun...
Introduction: Although antiretroviral therapy (ART) has been rapidly scaled up in Asia, most HIV-pos...
Background: Random effects models were used to explore how the shape of CD4 cell count responses aft...
Background Early initiation of combination antiretroviral therapy (cART), at higher CD4 cell coun...
Background Combination antiretroviral therapy (cART) has been shown to reduce mortality and morbidi...
The introduction of combination antiretroviral treatment (ART) has had substantial impact on the hum...
Early initiation of combination antiretroviral therapy (cART), at higher CD4 cell counts, prevents d...
Objective: To examine CD4 cell responses to combination antiretroviral therapy (cART) in patients en...
BACKGROUND: CD4+ cell counts reflect immunologic status of human immunodeficiency virus (HIV) patien...
BACKGROUND: CD4+ T-cell recovery in patients with continuous suppression of plasma HIV-1 viral load ...
Background: Currently, because of the wide availability and free service of HAART, HIV/AIDS related ...
INTRODUCTION The World Health Organization (WHO) recommends a CD4 cell count before starting anti...
BACKGROUND: Although the kinetics of CD4(+) cell counts have been extensively studied in antiretrovi...
ObjectiveTo assess whether the benefit of highly active antiretroviral therapies (HAART) is continui...